<VariationArchive VariationID="456333" VariationName="NM_032444.4(SLX4):c.5229dup (p.Gln1744fs)" VariationType="Duplication" Accession="VCV000456333" Version="29" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-07-15" DateCreated="2017-12-26" MostRecentSubmission="2024-07-15">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="465675" VariationID="456333">
      <GeneList>
        <Gene Symbol="SLX4" FullName="SLX4 structure-specific endonuclease subunit" GeneID="84464" HGNC_ID="HGNC:23845" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>16p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="3581181" stop="3611606" display_start="3581181" display_stop="3611606" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="3631181" stop="3661584" display_start="3631181" display_stop="3661584" Strand="-" />
          </Location>
          <OMIM>613278</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_032444.4(SLX4):c.5229dup (p.Gln1744fs)</Name>
      <CanonicalSPDI>NC_000016.10:3582617:C:CC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>16p13.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="3582617" stop="3582618" display_start="3582617" display_stop="3582618" variantLength="1" positionVCF="3582617" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="3632618" stop="3632619" display_start="3632618" display_stop="3632619" variantLength="1" positionVCF="3632618" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
      </Location>
      <ProteinChange>Q1744fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_503t1" sequenceAccession="LRG_503t1" change="c.5229dup">
            <Expression>LRG_503t1:c.5229dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_503" sequenceAccession="LRG_503" change="g.33967dup">
            <Expression>LRG_503:g.33967dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.10" sequenceAccession="NC_000016" sequenceVersion="10" change="g.3582618dup" Assembly="GRCh38">
            <Expression>NC_000016.10:g.3582618dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.3632619dup" Assembly="GRCh37">
            <Expression>NC_000016.9:g.3632619dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_028123.1" sequenceAccession="NG_028123" sequenceVersion="1" change="g.33967dup">
            <Expression>NG_028123.1:g.33967dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_032444.4" sequenceAccession="NM_032444" sequenceVersion="4" change="c.5229dup" MANESelect="true">
            <Expression>NM_032444.4:c.5229dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_115820.2" sequenceAccession="NP_115820" sequenceVersion="2" change="p.Gln1744fs">
            <Expression>NP_115820.2:p.Gln1744fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_032444.2" sequenceAccession="NM_032444" sequenceVersion="2" change="c.5229dupG">
            <Expression>NM_032444.2:c.5229dupG</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA7865370" DB="ClinGen" />
        <XRef Type="rs" ID="781479923" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00000" Source="The Genome Aggregation Database (gnomAD), exomes" />
        <AlleleFrequency Value="0.00001" Source="Exome Aggregation Consortium (ExAC)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_032444.4(SLX4):c.5229dup (p.Gln1744fs) AND Fanconi anemia" Accession="RCV000531680" Version="7">
        <ClassifiedConditionList TraitSetID="6447">
          <ClassifiedCondition DB="MedGen" ID="C0015625">Fanconi anemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-06-13" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_032444.4(SLX4):c.5229dup (p.Gln1744fs) AND not provided" Accession="RCV001091529" Version="19">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2017-08-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-06-13" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2017-12-26" MostRecentSubmission="2024-07-15">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">19596235</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19596236</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24733792</ID>
        </Citation>
        <DescriptionHistory Dated="2022-08-22">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2022-08-07">
          <Description>Pathogenic/Likely pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2020-05-09">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="6447" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1797" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Fanconi anemia</ElementValue>
                <XRef ID="MONDO:0019391" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS227650" DB="OMIM" />
                <XRef ID="84" DB="Orphanet" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Fanconi pancytopenia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Fanconi's anemia</ElementValue>
                <XRef ID="Fanconi+Anemia/2780" DB="Genetic Alliance" />
                <XRef ID="30575002" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">FA</ElementValue>
                <XRef Type="MIM" ID="227650" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.</Attribute>
                <XRef ID="NBK1401" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6425" />
                <XRef ID="6425" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301575</ID>
                <ID Source="BookShelf">NBK1401</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="PubMed">18197057</ID>
                <ID Source="pmc">3110977</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19888064</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="FARF, 2008">
                <URL>http://www.fanconi.org/images/uploads/other/Guidelines_for_Diagnosis_and_Management.pdf</URL>
                <CitationText>Fanconi Anemia Research Fund, Guidelines for Diagnosis and Management (3rd Ed.), 2008 (See 2020 Update)</CitationText>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Skin Cancer">
                <ID Source="PubMed">26389333</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2020">
                <URL>https://www.fanconi.org/explore/clinical-care-guidelines</URL>
                <CitationText>Fanconi Anemia Clinical Care Guidelines, Fifth Edition.</CitationText>
              </Citation>
              <XRef ID="84" DB="Orphanet" />
              <XRef ID="C0015625" DB="MedGen" />
              <XRef ID="D005199" DB="MeSH" />
              <XRef ID="MONDO:0019391" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS227650" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1218641" SubmissionDate="2024-02-07" DateLastUpdated="2024-02-28" DateCreated="2017-12-26">
        <ClinVarSubmissionID localKey="1125118|MedGen:C0015625" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000626448" DateUpdated="2024-02-28" DateCreated="2017-12-26" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-06-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">24733792</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19596235</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19596236</ID>
          </Citation>
          <Comment>This variant is present in population databases (rs781479923, ExAC 0.002%). This variant has been reported in an individual affected with breast cancer (PMID: 24733792). This sequence change results in a premature translational stop signal in the SLX4 gene (p.Gln1744Alafs*34). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 91 amino acids of the SLX4 protein. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. No experimental studies have been performed to test the effects of this variant on SLX4 protein function or stability. However, it is expected to result in the disruption of the last 91 amino acids (Gln1744-Asn1834) of the SLX4 protein. This removes most of the SLX1 interaction domain, which has been shown to be critical for SLX1-SLX4 complexing, and therefore will affect their Holliday junction resolvase and 5'-flap endonuclease activities (PMID: 19596235, 19596236).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLX4" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.9:g.3632618_3632619insC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0015625" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12506961</SubmissionName>
          <SubmissionName>SUB14200269</SubmissionName>
          <SubmissionName>SUB3109251</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2469243" SubmissionDate="2024-07-04" DateLastUpdated="2024-07-15" DateCreated="2020-05-12">
        <ClinVarSubmissionID localKey="101630|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001247644" DateUpdated="2024-07-15" DateCreated="2020-05-12" Type="SCV" Version="23" SubmitterName="CeGaT Center for Human Genetics Tuebingen" OrgID="505870" OrganizationCategory="laboratory" OrgAbbreviation="CHGT" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-08-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">CeGaT Center For Human Genetics Tuebingen Variant Classification Criteria Version 2</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/0ynenhfo/cegat_center_for_human_genetics_tuebingen_-_variant_classification_criteria_-_version_2.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLX4" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="16" alternateAllele="GC" referenceAllele="G" start="3632618" stop="3632618" variantLength="1" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2021-07</SubmissionName>
          <SubmissionName>2021-10</SubmissionName>
          <SubmissionName>2022-01</SubmissionName>
          <SubmissionName>2022-01-corrected</SubmissionName>
          <SubmissionName>2022-04</SubmissionName>
          <SubmissionName>2022-07</SubmissionName>
          <SubmissionName>2022-08</SubmissionName>
          <SubmissionName>2022-10.3</SubmissionName>
          <SubmissionName>2023-01</SubmissionName>
          <SubmissionName>2023-04</SubmissionName>
          <SubmissionName>2023-09-add-ACMG-details</SubmissionName>
          <SubmissionName>2023-10</SubmissionName>
          <SubmissionName>2024-04</SubmissionName>
          <SubmissionName>SUB13641132</SubmissionName>
          <SubmissionName>SUB13985080</SubmissionName>
          <SubmissionName>SUB14102099</SubmissionName>
          <SubmissionName>SUB14290090</SubmissionName>
          <SubmissionName>SUB14426581</SubmissionName>
          <SubmissionName>SUB14513473</SubmissionName>
          <SubmissionName>SUB14584463</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2469243" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1218641" TraitType="Disease" MappingType="XRef" MappingValue="C0015625" MappingRef="MedGen">
        <MedGen CUI="C0015625" Name="Fanconi anemia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

